You recall correctly—SIIO are the only ones (MB excluded) who...

You recall correctly—SIIO are the only ones (MB excluded) who truly get it.

They understand the massive value opportunity that life sciences are sitting on.

At this stage, I wouldn’t be surprised to see them taking a slice of the company or picking up the shortfall of shares not allocated at 2.5 cents.

Alternatively, they could opt for a funding arrangement with future buy-in clauses and/or profit-sharing structures.

With $7 million, they could secure up to 37% of the company and provide a full year of runway until the end of 2026.

and/or they after visiting to make a large order for a vaccine?

Time is ticking—only 16 days left in the month of May, and there’s bound to be movement at the station.